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Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) arising from an interaction between 
genetic and environmental factors.1, 2  
In UC, the anti-tumor necrosis factor (TNF) infliximab, a chimeric IgG1 antibody, is approved to treat 
patients with steroid-refractory or steroid-dependent disease. The undoubted benefits of a better disease 
control are partly limited by the high cost of the infliximab originator (Remicade). 
The biosimilar infliximab CT-P13 was approved for UC in Europe based on two randomised controlled 
trials in patients naïve to TNF inhibitors, comparing infliximab originator with CT-P13 in ankylosing 
spondylitis (PLANETAS, a phase 1 study) and rheumatoid arthritis (PLANETRA, a phase 3 study).3 
This extrapolation of indication has been debated in gastroenterology because the mechanisms of 
action for infliximab might differ between indications.4 
To date a fair number of studies about switching from infliximab originator to infliximab biosimilar in 
UC have been available from open cohort studies in secondary or tertiary centres.5-13 
A randomised, double-blind, parallel-group, multicentre, non-inferiority (non-inferiority margin of 
15%) trial (NOR-SWITCH) was the first study to show that switching from an originator to a 
biosimilar TNF inhibitor was not inferior to continued treatment with the originator drug.14 The authors 
calculated that 394 patients were required to exclude a difference in favour of infliximab originator. For 
the originator the risk difference of disease worsening was not statistically significant. The presumption 
of the study should be that, being involved patients with different immune-mediated disorders, the 
conclusions should be extended to all six relevant indications. Nevertheless, the authors highlighted 
that the study was not powered to show non-inferiority in individual diseases. So, also the data obtained 
by this study do not definitively resolve the issue of the equivalence between originator and CT-P13 in 
the individual diseases. 
   Tursi et al. recently published a prospective, observational, multicentre study performed in primary 
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IBD centres in Italy in which 29 adult outpatients with UC were treated with biosimilar infliximab CT-
13 between 1st of May 2015 and 1st of October 2016 and a 12-month follow-up was performed (where 
available).15 A group of patients was naïve to infliximab, another group switched Remicade to 
biosimilar infliximab CT-P13. The need of treatment discontinuation was left to the investigators’ 
judgement, as well as concomitant medications including oral and topical aminosalicylates, steroids 
and immunosuppressants.  
No adverse events were observed during follow-up, confirming the good safety profile of the drug. 
The authors concluded that biosimilar IFX CT-P13 was effective in real life even when managed in 
primary IBD centres. They argued that their results were better, regarding clinical response, mucosal 
healing and clinical remission, than those reported in literature. However, it should be noted that the 
reported efficacy derives from a per protocol analysis: the data of 100% of clinical remission and of 
mucosal healing come from the only 6 (of 29 enrolled) patients that concluded the 12 months follow 
up. The data from an intention to treat analysis, when all the patients will have concluded the follow 
up, or at least more details on why other patients have stopped taking infliximab, will be of great 
clinical interest.  
   In conclusion, data from randomised clinical trials and from primary IBD centres are in the right 
direction to provide us more data on the equivalence between infliximab originator and the biosimilar 
infliximab CT-P13, but larger cohort and intention to treat analysis are needed to obtain the definitive 
answer. 
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